Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIO-201 for Persistent Corneal Epithelial Defects
NCT05436288Phase 2Completed
- Sponsor
- Kiora Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, Hydrogel Systems
- Countries
- 1
01
Overview
A Phase 2 trial of KIO-201 in persistent corneal epithelial defect (PED), sponsored by Kiora Pharmaceuticals. Started Jul 2022; status: completed.
02
Drugs
KIO-201
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT05436288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436288.